Abstract
GemVax AS, a subsidiary of Pharmexa A/S, is developing GV-1001, an injectable formulation of a promiscuous MHCclass II peptide derived from the telomerase reverse transcriptase catalytic subunit (hTERT), for the potential treatment of solid tumors, including pancreatic, liver and NSCLC. GV-1001 is currently undergoing phase II clinical trials for pancreatic, liver and NSCLC as well as a phase III trial for pancreatic cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 490-497 |
| Number of pages | 8 |
| Journal | Current Opinion in Molecular Therapeutics |
| Volume | 9 |
| Issue number | 5 |
| State | Published - 2007 |
| Externally published | Yes |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Pharmacology
- Drug Discovery
- Genetics(clinical)